ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.282,18
-0,48%
S&P 500
6.012,28
-1,46%
Dow Jones
44.713,58
0,65%
Euro vs US Dollar
1,04925
-0,10%
Bitcoin
101.550,17
-2,98%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Becton Dickinson and Company (BDX)

  7. Becton Dickinson and Company (BDX) News

BDX

Becton Dickinson (BDX)

Becton Dickinson and Company
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:BDX
DatumZeitQuelleÜberschriftSymbolFirma
23/01/202513h15PR Newswire (US)BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and DevelopmentNYSE:BDXBecton Dickinson and Company
23/01/202512h45Business WireBD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and DevelopmentNYSE:BDXBecton Dickinson and Company
22/01/202515h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
22/01/202515h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
22/01/202512h50PR Newswire (US)Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of CareNYSE:BDXBecton Dickinson and Company
21/01/202522h21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:BDXBecton Dickinson and Company
21/01/202519h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:BDXBecton Dickinson and Company
21/01/202514h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
17/01/202522h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:BDXBecton Dickinson and Company
16/01/202522h15PR Newswire (US)BD to Announce Financial Results for its First Quarter of Fiscal 2025NYSE:BDXBecton Dickinson and Company
15/01/202512h50PR Newswire (US)BD Boosts U.S. Manufacturing of Critical Medical DevicesNYSE:BDXBecton Dickinson and Company
15/01/202512h50PR Newswire (Canada)New Survey Reveals Nearly 3 in 4 Canadian Women Are Delaying Their OB/GYN Exams, Increasing Risks for Cervical CancerNYSE:BDXBecton Dickinson and Company
15/01/202512h50PR Newswire (Canada)Une nouvelle enquête révèle que près de 3 Canadiennes sur 4 ratent leur examen gynécologique, augmentant ainsi les risques de cancer du col de l'utérus.NYSE:BDXBecton Dickinson and Company
13/01/202512h50PR Newswire (US)New ASCCP Guidelines Include More Precise Method of Cervical Cancer ScreeningNYSE:BDXBecton Dickinson and Company
10/01/202513h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
10/01/202512h59Edgar (US Regulatory)Form 8-K - Current reportNYSE:BDXBecton Dickinson and Company
10/01/202512h50PR Newswire (US)BD Names Pamela Spikner as Chief Accounting Officer and ControllerNYSE:BDXBecton Dickinson and Company
09/01/202512h50PR Newswire (US)New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical CancerNYSE:BDXBecton Dickinson and Company
07/01/202522h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:BDXBecton Dickinson and Company
07/01/202522h15PR Newswire (US)BD To Host Virtual 2025 Annual Meeting of ShareholdersNYSE:BDXBecton Dickinson and Company
07/01/202502h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
20/12/202416h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
19/12/202422h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:BDXBecton Dickinson and Company
19/12/202416h49Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNYSE:BDXBecton Dickinson and Company
19/12/202416h39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:BDXBecton Dickinson and Company
19/12/202416h36Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:BDXBecton Dickinson and Company
17/12/202412h50PR Newswire (US)BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care OrganizationsNYSE:BDXBecton Dickinson and Company
16/12/202422h32PR Newswire (US)BD Resolves Previously Disclosed SEC InvestigationNYSE:BDXBecton Dickinson and Company
11/12/202402h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
11/12/202402h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:BDXBecton Dickinson and Company
 Showing the most relevant articles for your search:NYSE:BDX

Kürzlich von Ihnen besucht

NASDAQ
GOOGL
Alphabet
CCOM
US30
US 30
COIN
AVAXUSD
Avalanche
USOTC
RHHBY
Roche (QX)
COIN
BTCUSD
Bitcoin
NASDAQ
TSLA
Tesla
TG
D7G
Nel ASA
FX
EURJPY
Euro vs Yen
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
CCOM
US100
US Tech 100
DBI
TDXP
Tec DAX
COIN
XRPUSD
Ripple
AMEX
XLE
Energy Select Sector SPDR
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten